|
1 |
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma
Enthalten in Bone marrow transplantation 13.2.2025: 1-6
|
|
|
2 |
Management of patients undergoing CAR-T cell therapy in Germany
Penack, Olaf. - Augsburg : Universität Augsburg, 2024
|
|
|
|
3 |
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Liebers, Nora. - Würzburg : Universität Würzburg, 2024
|
|
|
|
4 |
Barriers and Facilitators in Continuous Medical Education Related to Allogeneic Stem Cell Transplantation: A Qualitative Study of Physicians
Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 4: 136-144. 9 S.
|
|
|
|
5 |
Management of Patients Undergoing CAR-T Cell Therapy in Germany
Enthalten in Oncology research and treatment Bd. 47, 2024, Nr. 3: 65-75. 10 S.
|
|
|
|
6 |
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC)
Enthalten in Bone marrow transplantation 25.4.2024: 1-8
|
|
|
|
7 |
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison
Enthalten in Bone marrow transplantation 21.2.2024: 1-10
|
|
|
|
8 |
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
Bayas, Antonios. - Kiel : Universitätsbibliothek Kiel, 2023
|
|
|
|
9 |
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline
Bayas, Antonios. - Augsburg : Universität Augsburg, 2023
|
|
|
|
10 |
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation
Enthalten in Bone marrow transplantation 17.11.2023: 1-7
|
|
Administration
